Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Get smart on it
Enveda, a biotech startup that uses AI to discover drugs from plants and microbes rather than synthesizing them in labs, has raised $311 million in funding at a $2 billion valuation. The company was founded to speed up the drug discovery process using AI and related techniques. While no AI-discovered drugs have yet received FDA approval, Enveda is among companies moving AI-discovered drug candidates into human clinical trials, currently testing several drugs in patients including treatments for severe skin conditions and weight loss maintenance.
Related news
OpenAI nabs key Patreon execs ahead of upcoming announcement
Patreon co-founder Sam Yam is joing OpenAI to lead Creator Product. | Image: The Verge OpenAI has hired three former Patreon execs to anchor its product strategy for creators. After starting the creator subscription platform 13 years ago, co-founder and technology chief Sam Yam announced on X that he's joining OpenAI to lead Creator Product. He's also bringing Patreon's former product head Drew Rowny and engineering head Shannon Ma with him on the new venture, both of whom stepp
Ema raises $77M as AI starts eating into enterprise software and services
Ema has raised $140 million to date and has more than 50 enterprise customers, including Google and Microsoft.
